9edge
9edge
ALEMBICLTD PHARMA ACTIVE

Alembicltd Limited

Timeframe: WEEKLY CHART • Study Published: 04 Sep 2026, 02:53 PM
ENTRY PRICE
₹114
TARGET PRICE
₹135/150/165
STOPLOSS
₹85
Chart Levels & Structure
ALEMBICLTD Chart Click to Zoom
9edge
Alembicltd Limited (ALEMBICLTD)
RESEARCH & ANALYSIS STUDY RATIONALE
Complete Detailed Analysis & Research Rationale

ALEMBIC LTD

(NSE: ALEMBICLTD)


Business:

  • Alembic Ltd operates across Real Estate and API manufacturing
  • The company also holds a significant 28.54% stake in Alembic Pharmaceuticals, making the pharma holding an important part of its overall value

    • Q1 FY27 Performance 📊

  • Consolidated Revenue: ₹48.7 Cr
  • Consolidated PAT: ₹64.9 Cr
  • EPS: ₹2.53
  • The company also recognised ₹49.2 Cr as its share of profit from Alembic Pharmaceuticals during the quarter. (NSE India Search Archives)

    • Real Estate Business 🏗️

  • Real estate contributed approximately ₹370 Cr of segment revenue in Q1
  • Segment profit before tax and interest was approximately ₹140 Cr
  • This remains a major contributor to the company’s underlying asset value. (NSE India Search Archives)

    • Alembic Pharma Holding 💊

  • Alembic Ltd owns 28.54% of Alembic Pharmaceuticals
  • Alembic Pharmaceuticals delivered strong Q1 FY27 growth, with revenue of approximately ₹2,150 Cr, up 26% YoY
  • Pharma’s US formulations business grew strongly, while API and India branded businesses also expanded. (Alembic Limited)

    • Key Positives 🟢

  • Valuable listed pharma holding
  • Real estate assets provide another significant source of value
  • Strong contribution from the pharma associate
  • Diversified asset base across healthcare and real estate
  • Potential for the market to increasingly recognise the underlying value of these assets

    • What I’m Watching ⚠️

  • Real estate revenue can be lumpy depending on project completion and recognition
  • Alembic Ltd’s own core operating profit was weaker YoY in Q1
  • Valuation depends heavily on the market value and future performance of Alembic Pharmaceuticals
  • The discount between the company’s market value and underlying asset value is an important monitorable

    • Key Triggers 🚀

  • Continued growth at Alembic Pharmaceuticals
  • Stronger real estate project execution
  • Better monetisation of real estate assets
  • Reduction in holding company discount
  • Any corporate action involving the pharma holding or group restructuring

    • Overall View:


    Alembic Ltd is an interesting holding company plus real estate value story.


    The key attraction is the combination of 28.54% ownership in Alembic Pharmaceuticals + substantial real estate assets + API business.


    For me, the biggest monitorable is whether the market gradually starts assigning better value to these underlying assets instead of looking only at Alembic Ltd’s reported quarterly earnings.


    Technical Setup:

    👉 Refer to the chart for my technical levels, support/resistance zones and price action view.


    Disclaimer: Educational content only. Not investment advice. Please do your own research.

    9edge

    ©️ 2026 9edgeClub EquityEdge Research.

    Educational & Analytical Purpose Only.